SCHEMBL2060255

SCHEMBL2060255

COc1ccc(-c2cc3cc(CNc4cc(C(=O)NC5CC5)ccc4F)cnc3[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.47
KDR P35968 2/20 0.43
MAPK14 Q16539 3/20 0.43
CCR3 P51677 1/20 0.42
ULK1 O75385 1/20 0.42
VNN1 O95497 1/20 0.42
SMYD3 Q9H7B4 1/20 0.42
MAPK11 Q15759 1/20 0.41
MCHR1 Q99705 1/20 0.40
DCK P27707 1/20 0.40
CNR1 P21554 1/20 0.40
DRD4 P21917 1/20 0.40
HPGDS O60760 2/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
MAPT P10636 1/20 0.40
POLB P06746 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL885848 0.93 RIPK1 (0.47) RIPK1KDRMAPK14CCR3ULK1
SCHEMBL2060044 0.89 RIPK1 (0.51) RIPK1KDRMAPK14ULK1SMYD3
SCHEMBL885846 0.86 KDR (0.41) RIPK1KDRMAPK14SMYD3MAPK11
SCHEMBL885701 0.85 RIPK1 (0.52) RIPK1KDRMAPK14VNN1SMYD3
SCHEMBL885792 0.83 HDAC1 (0.43) RIPK1KDRMAPK14ULK1MCHR1
SCHEMBL2060127 0.82 KDR (0.54) RIPK1KDRMAPK14MAPK11MCHR1
SCHEMBL885592 0.81 KDR (0.48) RIPK1KDRMAPK14SMYD3MCHR1
SCHEMBL2060253 0.80 RIPK1 (0.48) RIPK1MAPK14ULK1SMYD3MAPK11
SCHEMBL885586 0.77 KIT (0.50) RIPK1KDRCCR3ULK1
SCHEMBL885847 0.74 RIPK1 (0.48) RIPK1ULK1SMYD3MCHR1DCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081928-B1 Pyrrolo-pyridine kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-02-26 EP claimed
US-8148361-B2 Kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US claimed
US-20100041636-A1 NOVEL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-18 US claimed
EP-2081928-B1 Pyrrolo-pyridine kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-02-26 EP disclosed
US-8148361-B2 Kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-8148361-B2 Kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-8148361-B2 Kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-20100041636-A1 NOVEL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-18 US disclosed
US-20100041636-A1 NOVEL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-18 US disclosed
US-20100041636-A1 NOVEL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-18 US disclosed
WO-2008060907-A2 PYRROLO-PYRIDINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041636-A1 NOVEL KINASE INHIBITORS IGF1R, FGFR1, FLT1 RIPK1 850/4885KDR 5/4885MAPK14 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.